Sinovac Biotech Ltd (SVA) stock
SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.47+0.00 (0.00%)
Close on Nov 17, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Sinovac Biotech's pe ratio was 5.1× on Feb 27, 2026, against 32.4× a year earlier. Over the last 5 years it ranged from 0.1× to 32.4×, with a median of 6.7×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Feb 27, 2026 | 5.1× | +0.0 |
| 2025 | Dec 31, 2025 | 5.1× | −27.3 |
| 2024 | Feb 29, 2024 | 32.4× | +0.0 |
| 2023 | Dec 29, 2023 | 32.4× | +32.3 |
| 2022 | Dec 30, 2022 | 0.1× | −6.6 |
| 2021 | Dec 31, 2021 | 6.7× | −9.1 |
| 2020 | Dec 31, 2020 | 15.8× | −3.2 |
| 2019 | Dec 31, 2019 | 19.0× | +3.6 |
| 2018 | Dec 31, 2018 | 15.4× | −22.6 |
| 2015 | Feb 27, 2015 | 38.0× | −2.2 |
| 2014 | Dec 31, 2014 | 40.2× | +30.4 |
| 2011 | Feb 28, 2011 | 9.8× | +0.0 |
| 2010 | Dec 31, 2010 | 9.8× | – |
See a number that looks wrong?